BEIJING, Nov. 7 /PRNewswire-FirstCall/ -- Medicsight Inc.'s majority owned subsidiary, Medicsight PLC, today announced the appointment of Gentle Hsieh to the newly created position of senior clinical product manager and the appointment of Ben Yang to the position of corporate executive. Both Hsieh and Yang will be based in Medicsight’s newly opened office, situated in the Chaoyang district in Beijing.
Hsieh will be responsible for the implementation of the recently announced Chinese clinical program. He joins Medicsight with more than five years of clinical product management experience, most recently serving within the Interventional Cardiology and Surgery division of GE Technologies. Prior to serving with GE, Hsieh served with a number of software-related companies and was a neurosurgeon for The Urumqi Military Hospital.
As a corporate executive for Medicsight, Yang will be responsible for overseeing the day-to-day activities for all corporate initiatives for Medicsight. This position was a natural progression for Yang who had been based at the Medicsight global headquarters in London.
Medicsight Asia CEO David Sumner said, “I am delighted to welcome Gentle and Ben to our growing Beijing team. Medicsight is committed to attracting and developing people of the highest caliber, and Gentle and Ben add two tremendous assets to our company. Together they will enhance our ability to support our expanding clinical program and execute our Chinese growth strategy. We believe Mr. Hsieh’s extensive clinical product management experience combined with Mr. Yang’s intimate familiarity with our company’s operations will allow them to seamlessly integrate into their new roles.”
Medicsight develops enterprise-wide computer-aided detection (CAD) software that is used by the medical imaging market to aid in earlier detection of disease. Tested on one of the world’s largest databases of verified CT scan data, Medicsight’s software solutions help clinicians identify, measure, and analyze suspicious pathology, such as colorectal polyps and lung lesions. The company’s CAD products include ColonCAD API, the first CAD technology available for CT colonography, and LungCAD API. Both products allow for a concurrent read that lets clinicians to review the original image simultaneously with the Medicsight CAD findings, which results in improved workflow and productivity. Medicsight continues to develop CAD software for a variety of disease states that can help in the early detection of disease and ultimately improve patient outcomes. Headquartered in London, Medicsight employs more than 60 people and also has offices in the United States, Japan, China, and Gibraltar. Product and company information can be found on http://www.medicsight.com . Stock symbol: OTC Bulletin Board: MSHT
All forward-looking statements are made pursuant to the ‘safe harbor’ provisions of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on current management expectations that involve risks and uncertainties that may result in such expectations not being realized. Potential risks and uncertainties include, but are not limited to, the risks described in company filings with the Securities and Exchange Commission.
Medicsight Inc.
CONTACT: Media, China, Dina Dong or Lindsay Liu, +86-10-5869 1666, orMedia, U.S.A., Lindsay Vidrine, +1-314-982-1723, or Investors, StephanieCarrington, +1-646-536-7017, or Nick Laudico, +1-646-536-7030 , all ofMedicsight Inc.
Web site: http://www.medicsight.com/
